| scholarly article | Q13442814 |
| P50 | author | Stefano Buda | Q90289119 |
| P2093 | author name string | Luca Degli Esposti | |
| Valentina Perrone | |||
| Roberta Rossini | |||
| Chiara Veronesi | |||
| Local Health Unit group | |||
| P2860 | cites work | 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q56674421 |
| Commentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trials | Q86358967 | ||
| Cardiovascular disease in Europe 2016: an epidemiological update | Q88783593 | ||
| ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) | Q22242892 | ||
| Antiplatelet and anticoagulation therapy for acute coronary syndromes | Q26824701 | ||
| Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study | Q28732420 | ||
| Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective | Q30884351 | ||
| Readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia among young and middle-aged adults: a retrospective observational cohort study | Q34275502 | ||
| 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati | Q34491521 | ||
| Risk factors for rehospitalization for acute coronary syndromes and unplanned revascularization following acute myocardial infarction | Q35135687 | ||
| Hospital readmissions reduction program | Q35631600 | ||
| Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents | Q35783487 | ||
| Thirty-day rehospitalizations after acute myocardial infarction: a cohort study | Q36474491 | ||
| Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention | Q36626647 | ||
| Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction | Q36706382 | ||
| Decade-Long Trends in 30-Day Rehospitalization Rates After Acute Myocardial Infarction | Q36836190 | ||
| Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia | Q36944057 | ||
| Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world' retrospective cohort study | Q37454789 | ||
| Antithrombotic strategies to reduce adverse clinical outcomes in patients with acute coronary syndrome | Q38030144 | ||
| Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial | Q38198195 | ||
| How can we optimize the processes of care for acute coronary syndromes to improve outcomes? | Q38273904 | ||
| Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy | Q38319773 | ||
| Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial | Q38443515 | ||
| Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart | Q38795916 | ||
| Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial | Q39646950 | ||
| Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population. | Q40165721 | ||
| Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. | Q40461267 | ||
| Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial | Q41367415 | ||
| Hospital readmission as an accountability measure | Q43779584 | ||
| Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization | Q47634232 | ||
| Short- and long-term cause of death in patients treated with primary PCI for STEMI. | Q48431119 | ||
| Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology | Q48793852 | ||
| Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. | Q51067690 | ||
| Challenges in secondary prevention after acute myocardial infarction: A call for action. | Q52847951 | ||
| Acute myocardial infarction | Q54069247 | ||
| Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis. | Q54588148 | ||
| ??? | Q22242895 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | platelet aggregation | Q14913634 |
| myocardial infarction | Q12152 | ||
| acute myocardial infarction | Q18558122 | ||
| P304 | page(s) | 383-392 | |
| P577 | publication date | 2018-11-20 | |
| P1433 | published in | Vascular Health and Risk Management | Q7916443 |
| P1476 | title | All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-aggregation Inhibition: Persistence with treatment and cardiovascular Events in Real world (PIPER) study | |
| P478 | volume | 14 |
Search more.